findmyKOL
Clinical trialNCT06773936Enrolling, by, invitationPhase 2Interventional

Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

SponsorSWOG Cancer Research NetworkEnrollment55CD19+ Acute LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial is to answer the question of "can adding the study drug, asciminib to usual treatment improve how chemotherapy works against Ph+ Acute Lymphoblastic Leukemia (ALL) and is this approach better than the usual approach for Ph+ALL?"
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Uc Irvine Medical Center

    Orange, California, United States

  • Henry Ford Hospital

    Detroit, Michigan, United States

  • University of New Mexico Cancer Center

    Albuquerque, New Mexico, United States

  • Northwell Health/center for Advanced Medicine

    Lake Success, New York, United States

  • University of Rochester Medical Center

    Rochester, New York, United States

  • Duke University Medical Center

    Durham, North Carolina, United States

  • University of Cincinnati Cancer Ctr-Uc Medical Ctr

    Cincinnati, Ohio, United States

  • Cleveland Clinic Foundation

    Cleveland, Ohio, United States

  • Upmc Hillman Cancer Center

    Pittsburgh, Pennsylvania, United States

  • Rhode Island Hospital

    Providence, Rhode Island, United States

  • Baptist Memorial Health Care

    Memphis, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Induction PhaseMaintenancePost-RemissionRe-Induction Phase
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
13 Apr 2026
Primary completion
31 May 2029
Completion
31 Jul 2033
Last update posted
11 Aug 2026
Registered enrollment
55
Registry id
NCT06773936
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.